Advertisement

Topics

Aimmune Therapeutics, Inc. Company Profile

07:07 EDT 22nd September 2018 | BioPortfolio

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Aimmune Therapeutics’ characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), combines proprietary product candidates with gradual, controlled up-dosing protocols to obtain meaningful desensitization to food allergens. Aimmune Therapeutics recently completed a Phase 2 study of its lead product, AR101, a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies. Aimmune Therapeutics is also developing products for other common food allergies for use with the CODIT system. For more information, please see www.aimmune.com.


News Articles [757 Associated News Articles listed on BioPortfolio]

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, ...

www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of...

Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: R...

Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy

BRISBANE, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food ...

Aimmune expects FDA decision on peanut allergy therapy in August 2019

Aimmune Therapeutics anticipates an FDA advisory committee meeting for the approval of its lead oral immunotherapy candidate AR101 evaluated to treat peanut allergies,...Read More... The post Aimmu...

Aimmune to file peanut allergy treatment by year-end

Biotech company Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following its major phase 3 trial success. Aimmune saw its shares surge last month a...

Public offering nets $190mm for Aimmune

Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $190mm through a public offering of 6.3mm common shares (including the overallotment) at $32. Proceeds are earmarked for continued devel...

Aimmune Therapeutics: Special Situation Biotech Opportunity

Aimmune Therapeutics (AIMT) Investor Presentation - Slideshow

PubMed Articles [436 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [154 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1256 Associated Companies listed on BioPortfolio]

Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food a...

Aimmune Therapeutics Inc.

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensit...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Aimmune Therapeutics, Inc." on BioPortfolio

We have published hundreds of Aimmune Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aimmune Therapeutics, Inc. Clinical Trials and PubMed Articles about Aimmune Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aimmune Therapeutics, Inc. Companies in our database. You can also find out about relevant Aimmune Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...


Corporate Database Quicklinks



Searches Linking to this Company Record